Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes

International Journal of Urology

Volumn 14, Issue 9, 2007, Pages 795-799

  Nagao, Keiji ^a   Itoh, Yukio ^a   Fujita, Kazuhiko ^b   Fujime, Makoto ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shizuoka Hospital   (Japan)

Author keywords

Bladder cancer; CA19 9; Cut off valuew; Lewis genotype; Secretor genotype

Indexed keywords

CA 19-9 ANTIGEN; DUPAN 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD GROUP LEWIS SYSTEM; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 34548175152     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01840.x     Document Type: Article

References (16)

1. Tizzani A, Cassetta G, Cicigoi A et al. Tumor markers (CEA, TPA and CA19-9) in urine of bladder cancer patients. Int. J. Biol. Markers 1987 2:121 4.
2. Mansour OA, Shouman SA, Khafagy M et al. Urinary CA19-9 as marker for bladder cancer. Lancet 1995 346:512 13.
3. Vestergaard EM, Wolf H, Orntoft TF. Increased concentrations of genotype-interpreted CA19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium. Clin. Chem. 1998 44:197 204.
4. Noto K, Fujime S, Isobe H, Wakumoto Y, Kawachi Y. Determination of urinary CA19-9 levels in urothelial cancer - assessment of its role in diagnosis. Nippon Hinyokika Gakkai Zasshi 1997 88:406 13.
5. Tizzani A, Cassetta G, Piana P, Piantino P. CA19-9 as serum marker in transitional bladder carcinoma. J. Tumor Marker Oncol. 1988 3:447 9.
6. Narimatsu H, Iwasaki H, Nishihara S et al. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res. 1996 56:330 8.
7. Narimatsu H, Iwasaki H, Nakayama F et al. Lewis and Secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998 58:512 18.
8. Nagao K, Itoh Y, Fujime S. Progress in Forensic Genetics, In:Sensabaugh GF, Loncoln PJ, Olaisen B (eds). Influence of Lewis blood group genotypes for CA19-9 leveles in urine and serum from urologic disease. Elsevier, Amsterdam:2000 8 (ICS 1193):574 77.
9. Satoh K, Takahashi K, Itoh Y. Comparative studies of Lewis genotyping by three PCR methods. DNA Polymorph. 2004 12:131 4.
10. Nishihara S, Narimatsu H, Iwasaki H et al. Molecular genetic analysis of the human Lewis histo-blood group system. J. Biol. Chem. 1994 269:29 71 8.
11. Itoh Y, Takahashi K, Satoh K, Nagao K, Fujime M. Progress in Forensic Genetics, In:Doutremepuich C, Morling N (eds). Multiplex PCR with confronting two-pair primers for Se genotyping. Elsevier, Amsterdam:2004 10 (ICS 1261):602 4.
12. Kudo T, Iwasaki H, Nishihara S et al. Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. J. Biol. Chem. 1996 271:9830 7.
13. Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha (1,2) fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J. Biol. Chem. 1995 270:4640 9.
14. Koda Y, Soejima M, Liu Y, Kimura H. Molecular basis for secretor type alpha (1,2)-fucosyltransferase gene deficiency in a Japanese population: A fusion gene generated by unequal crossover responsible for the enzyme deficiency. Am. J. Hum. Genet. 1996 59:343 50.
15. Itoh Y, Satoh K, Takahashi K, Nagao K, Fujime M. Genotype frequency of Lewis and Se blood groups in Japanese. DNA Polymorph. 2004 12:267 9.
16. Fujita K, Itoh Y, Wada R, Nagao K, Fujime M. Embryonal carcinoma producing DU-PAN-2 with burned-out phenomenon in the testis. Int. J. Urol. 2006 13:473 5.